BiotechTube

Tofersen

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Conditions

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Trial Timeline

Mar 8, 2017 → Aug 12, 2024

NCT ID
NCT03070119

About Tofersen

Tofersen is a phase 3 stage product being developed by Biogen for ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT03070119. Target conditions include ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation.

What happened to similar drugs?

1 of 5 similar drugs in ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation were approved

Approved (1) Terminated (1) Active (3)
✅13-valent Pneumococcal conjugate vaccinePfizerApproved
🔄RotaTeq (V260) + IPVMerckPhase 3
❌Ceftolozane-Tazobactam + MeropenemMerckPhase 3
🔄Hib-CRM197 + Hib-TTNovartisPhase 3
🔄Elinzanetant (BAY3427080) + PlaceboBayerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT04972487Pre-clinicalCompleted
NCT07259980Pre-clinicalRecruiting
NCT07294144Phase 2Recruiting
NCT07223723ApprovedRecruiting
NCT03070119Phase 3Completed

Competing Products

7 competing products in ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

See all competitors
ProductCompanyStageHype Score
E3810 + E3810 + TeprenoneEisaiPhase 2/3
38
Rabeprazole + RabeprazoleEisaiPhase 2/3
38
RotaTeq (V260) + IPVMerckPhase 3
40
Ceftolozane-Tazobactam + MeropenemMerckPhase 3
32
Hib-CRM197 + Hib-TTNovartisPhase 3
40
13-valent Pneumococcal conjugate vaccinePfizerApproved
43
Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
41